Replies to post #69099 on Biotech Values

[mcbio]

Thanks for the welcome! Happy thanksgiving to you and everyone else on here. This is a cool site. I wish I'd found this a long time ago as I've been investing in biotechs for years.

I'm going to read MNTA's latest 10-Q to get a better feel for this company but I like everything I've read so far. Do you have any idea what the exact royalty will be for MNTA on sales of generic Lovenox if there are multiple generic competitors? I'd assume it's still a double-digit royalty.

Is MNTA your favorite biotech stock right now Dew?

[Biopharm investor]

enoxaparin competition

In light of the recent discussions here I jumped over to read some of the information on MNTA. The post to which I am replying states:

"A key issue from a valuation standpoint is whether MNTA/NVS obtains the only FDA approval of a generic Lovenox or whether the competitors—Teva and Amphastar—also get approval."

At least four companies have filed ANDAs with Paragraph IV certification for generic versions of Lovenox (enoxaparin sodium): Teva, Amphastar, MNTA/Sandoz, and Hospira.

[DewDiligence]

MNTA – This is Sanofi’s official 2009 guidance:

http://finance.yahoo.com/news/Sanofiaventis-Delivers-2008-prnews-14321033.html

In 2009, sanofi-aventis expects growth in adjusted EPS excluding selected items of at least 7% at constant exchange rates, barring major adverse events such as the launch of a generic of Lovenox in the United States.

As previously noted on this board, if MNTA/Sandoz obtain the only FDA-approved generic for Lovenox, it will be the largest-selling generic drug of all time by a wide margin and clearly a “major adverse event” for Sanofi!